Smith, Ian P. http://orcid.org/0000-0002-1236-2872
DiSantostefano, Rachael L. http://orcid.org/0000-0002-5324-6835
de Bekker-Grob, Esther W. http://orcid.org/0000-0001-7645-6168
Levitan, Bennett http://orcid.org/0000-0001-9069-8446
Berlin, Conny http://orcid.org/0000-0002-5904-5057
Veldwijk, Jorien http://orcid.org/0000-0003-4822-5068
de Wit, G. Ardine http://orcid.org/0000-0002-1375-7657
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (115966)
Article History
Accepted: 18 February 2021
First Online: 15 March 2021
Declarations
:
: The PREFER project has received funding from the IMI 2 Joint Undertaking under grant agreement number 115966. This joint undertaking receives support from the EU’s Horizon 2020 Research and Innovation Program and the EFPIA.
: Conny Berlin is employed by, owns stock in, and has stock options in Novartis Pharma AG, which is one of the industry partners in the PREFER Project. Rachael DiSantostefano and Bennett Levitan are employed by Janssen Research and Development, LLC, and are stockholders in Johnson & Johnson. Bennett Levitan also owns stock in a variety of companies that at times include other pharmaceutical and health care-related companies. Ian P. Smith, Esther W. de Bekker-Grob, Jorien Veldwijk, and G. Ardine de Wit declare they have no conflicts of interests that are relevant to the contents of this article.
: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: IS created the first draft of this commentary in collaboration with RD. All authors were contributors to the PREFER research agenda technical report, on which this commentary is based, and all authors reviewed and provided comments on the draft and approved the final version before submission.